SHORT HILLS, N.J.--(BUSINESS WIRE)--June 29, 2006--Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC - News) announced today that the company is beginning a Phase IIb, multi-center, randomized, double-blinded trial to evaluate the efficacy and safety of the investigational drug seliciclib (CYC202), an orally available molecule that targets cyclin dependent kinases (CDKs), as a third line treatment in patients with non-small cell lung cancer (NSCLC). The trial is being initiated following Food and Drug Administration (FDA) and central Institutional Review Board (IRB) approval of the trial protocol. The “APPRAISE” study builds on the observation of prolonged stable disease experienced by heavily-pretreated NSCLC patients enrolled in a Phase I study of single agent seliciclib.
